

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior claim listings.

1. (Currently Amended) An expression vector comprising the nucleic acid sequence CEA(6D)-1,2 as illustrated in SEQ ID NO.: ~~24~~ 28 and Figure 9 or a fragment thereof.
2. (Original) The expression vector of claim 1 wherein the vector is a plasmid or a viral vector.
3. (Original) The expression vector of claim 2 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
4. (Currently Amended) The expression vector of claim 3 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
5. (Currently Amended) The expression vector of claim 4 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
6. (Currently Amended) The expression vector of claim 1 further comprising at least one additional nucleic acid encoding a tumor-associated antigen.
7. (Original) The expression vector of claim 6 wherein the vector is a plasmid or a viral vector.
8. (Original) The expression vector of claim 7 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
9. (Currently Amended) The expression vector of claim 8 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
10. (Currently Amended) The expression vector of claim 9 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
11. (Original) The expression vector of claim 1 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.

12. (Original) The expression vector of claim 11 wherein the vector is a plasmid or a viral vector.
13. (Original) The expression vector of claim 12 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
14. (Currently Amended) The expression vector of claim 13 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
15. (Currently Amended) The expression vector of claim 14 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
16. (Original) The expression vector of claim 6 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
17. (Original) The expression vector of claim 16 wherein the vector is a plasmid or a viral vector.
18. (Original) The expression vector of claim 17 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
19. (Currently Amended) The expression vector of claim ~~17~~ 18 wherein the ~~viral vector~~ ~~is a~~ poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
20. (Currently Amended) The ~~poxvirus~~ expression vector of claim ~~18~~ 19 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
21. (Original) The expression vector of claim 1, 6, 11 or 16 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
22. (Currently Amended) The expression vector of claim ~~22~~ 21 wherein the vector is a plasmid or a viral vector.
23. (Currently Amended) The expression vector of claim ~~23~~ 22 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.

24. (Currently Amended) The expression vector of claim ~~24~~ 23 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
25. (Currently Amended) The ~~poxvirus~~ expression vector of claim ~~18~~ 24 wherein the ~~viral vector is a poxvirus~~ is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
26. (Currently Amended) A composition comprising an expression vector comprising the nucleic acid sequence CEA(6D)-1,2 as illustrated in SEQ ID NO.: 24 28 and Figure 9 or a fragment thereof in a pharmaceutically acceptable carrier, ~~said vector comprising the nucleic acid sequence CEA(6D)-1,2 as illustrated in SEQ ID NO.: 24 28 and Figure 9 or a fragment thereof.~~
27. (Currently Amended) The ~~expression vector~~ composition of claim 26 wherein the vector is a plasmid or a viral vector.
28. (Currently Amended) The ~~expression vector~~ composition of claim 27 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
29. (Currently Amended) The ~~expression vector~~ composition of claim 28 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
30. (Currently Amended) The ~~poxvirus~~ composition of claim 29 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
31. (Currently Amended) A method for preventing or treating cancer comprising administering to a host an expression vector comprising the nucleic acid sequence CEA(6D)-1,2 as illustrated in SEQ ID NO.: ~~24~~ 28 and Figure 9 or a fragment thereof.
32. (Currently Amended) The ~~expression vector~~ method of claim 31 wherein the vector is a plasmid or a viral vector.
33. (Currently Amended) The ~~expression vector~~ method of claim 32 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.

34. (Currently Amended) The ~~expression vector~~ method of claim 33 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
35. (Currently Amended) The ~~poxvirus~~ method of claim 34 wherein the ~~viral vector is a~~ poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
36. (Currently Amended) An isolated DNA molecule comprising the CEA(6D)-1,2 sequence illustrated in SEQ ID NO.: ~~24~~ 28 and Figure 9.
37. (Currently Amended) An isolated DNA molecule comprising a fragment of the CEA(6D)-1,2 sequence illustrated in SEQ ID NO.: ~~24~~ 28 and Figure 9.
38. (New) An expression vector comprising a nucleic acid of SEQ ID NO: 28.
39. (New) The expression vector of claim 38 further comprising a nucleic acid sequence encoding a co-stimulatory molecule.
40. (New) The expression vector of claim 39 wherein the co-stimulatory molecule is human B7.1.
41. (New) The expression vector of claim 38 further comprising a nucleic acid sequence encoding at least one additional tumor-associated antigen.
42. (New) The expression vector of claim 38 further comprising a nucleic acid sequence encoding at least one angiogenesis-associated antigen.
43. (New) A composition comprising an expression vector of any one of claims 38-42 in a pharmaceutically acceptable carrier.
44. (New) An isolated nucleic acid molecule comprising SEQ ID NO: 28.
45. (New) An isolated nucleic acid molecule comprising a fragment of SEQ ID NO: 28, the fragment including at least nucleotides 421-1490 thereof.
46. (New) The isolated nucleic acid molecule of claim 44 or 45 further comprising a nucleic acid sequence encoding a co-stimulatory molecule.
47. (New) The isolated nucleic acid molecule of claim 46 wherein the co-stimulatory molecule is human B7.1.
48. (New) The isolated nucleic acid molecule of claim 44 or 45 further comprising a nucleic acid sequence encoding at least one additional tumor-associated antigen.
49. (New) The isolated nucleic acid molecule of claim 44 or 45 further comprising a nucleic acid sequence encoding at least one angiogenesis-associated antigen.

50. (New) A composition comprising an isolated nucleic acid molecule of any one of claims 44-49 in a pharmaceutically acceptable carrier.